08 Nov SAHPRA’s position on GLP1 and GIP-GLP1 products that are compounded, substandard and falsified
Pretoria, 08 November 2024 –The South African Health Products Regulatory Authority (SAHPRA) is concerned about the proliferation of falsified, compounded and substandard Glucagon-like Peptide (GLP-1)-containing products being made available to the public via websites, social media platforms and other informal channels. These pose a health...